SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 3 analyzed stories

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $269 million and 400 net patient additions, and reiterated full-year revenue guidance of $1.0 billion to $1.04 billion. It also reported favorable safety, tolerability, and drug-level data from a multiple-dose study of BP-205.

Published:

Updated:

What happened

Harmony Biosciences reported that WAKIX brought in $269 million in third-quarter 2026 revenue, with 400 net patient additions. The company kept its full-year revenue outlook at $1 billion to $1.04 billion. It also said BP-205 study results support further development.

Global impact / market context

WAKIX revenue growth may matter to investors, but operating and net income declined as royalty payments and research spending rose. Progress with BP-205 could add to the company’s future options, while litigation and a competitor’s launch remain risks.

What to watch

  1. Check whether WAKIX revenue and patient additions continue to grow; they show how the product is performing.
  2. Check future operating and net income; higher royalty payments and research spending weighed on recent earnings.
  3. Check for updates on BP-205, litigation, and the competitor launch; these could affect the company’s development plans and outlook.

Affected assets

  • Harmony Biosciences Holdings, Inc.

Evidence